Caterina Motta
Overview
Explore the profile of Caterina Motta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1742
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Assogna M, Di Lorenzo F, Bonni S, Borghi I, Cerulli Irelli E, Mencarelli L, et al.
Brain Commun
. 2025 Mar;
7(2):fcaf080.
PMID: 40046339
Frontotemporal dementia is a devastating neurodegenerative disorder for which no pharmacological treatments have been approved. Neuroinflammation plays a central role in driving the pathogenic mechanisms underlying frontotemporal dementia. In the...
2.
Bonomi C, Motta C, Di Donna M, Poli M, Nuccetelli M, Bernardini S, et al.
Alzheimers Res Ther
. 2024 Nov;
16(1):248.
PMID: 39550595
Background: The role of Vascular risk factors (VRFs) in the progression of Alzheimer's Disease (AD) and cognitive decline remains to be elucidated, with previous studies resulting in conflicting findings. The...
3.
Martorana A, Bonomi C, Di Donna M, Motta C
Neurol Ther
. 2024 Nov;
14(1):1-5.
PMID: 39487946
Lecanemab (Leqembi, Biogen), a humanized anti-amyloid-beta monoclonal antibody, has been approved for early-stage Alzheimer's disease (AD) in several countries, including the US and Japan. However, the European Medicines Agency (EMA)...
4.
Bernocchi F, Bonomi C, Assogna M, Moreschini A, Mercuri N, Koch G, et al.
Neurobiol Aging
. 2024 Jun;
141:66-73.
PMID: 38823205
Astrocytes in Alzheimer's disease (AD) exert a pivotal role in the maintenance of blood-brain barrier (BBB) integrity essentially through structural support and release of soluble factors. This study provides new...
5.
Constitutive NOS Production Is Modulated by Alzheimer's Disease Pathology Depending on APOE Genotype
Bonomi C, Martorana A, Fiorelli D, Nuccetelli M, Placidi F, Mercuri N, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612537
Both the endothelial (eNOS) and the neuronal (nNOS) isoforms of constitutive Nitric Oxide Synthase have been implicated in vascular dysfunctions in Alzheimer's disease (AD). We aimed to explore the relationship...
6.
Ricci F, Martorana A, Bonomi C, Serafini C, Mercuri N, Koch G, et al.
J Alzheimers Dis
. 2023 Dec;
97(2):599-607.
PMID: 38160356
Background: Blood-brain barrier (BBB) dysfunction could favor the pathogenesis and progression of Alzheimer's disease (AD). Vascular risk factors (VRF) could worsen BBB integrity, thus promoting neurode generation. Objective: To investigate...
7.
Bruno M, Bonomi C, Ricci F, Di Donna M, Mercuri N, Koch G, et al.
Eur J Neurol
. 2023 Oct;
31(1):e16095.
PMID: 37823706
Introduction: Inflammation is an important player in Alzheimer's disease (AD), whose effects can be influenced by the blood-brain barrier (BBB). Here, we investigated the relationship between BBB permeability, indicated by...
8.
Motta C, Di Donna M, Bonomi C, Assogna M, Chiaravalloti A, Mercuri N, et al.
Alzheimers Res Ther
. 2023 Aug;
15(1):144.
PMID: 37649105
Background: Despite the high sensitivity of cerebrospinal fluid (CSF) amyloid beta (Aβ) to detect amyloid pathology, the Aβ/Aβ ratio (amyR) better estimates amyloid load, with higher specificity for Alzheimer's disease...
9.
Bonomi C, Chiaravalloti A, Camedda R, Ricci F, Mercuri N, Schillaci O, et al.
Biomedicines
. 2023 Mar;
11(3).
PMID: 36979704
Glial and microglial cells contribute to brain glucose consumption and could actively participate in shaping patterns of brain hypometabolism. Here, we aimed to investigate the association between F-fluorodeoxyglucose (F-FDG) uptake...
10.
Bonomi C, Assogna M, Di Donna M, Bernocchi F, De Lucia V, Nuccetelli M, et al.
J Alzheimers Dis
. 2023 Mar;
92(4):1385-1397.
PMID: 36911936
Background: Many transversal mechanisms act synergistically at different time-points in the cascade of Alzheimer's disease (AD), since amyloid-β (Aβ) deposition, tau pathology, and neuroinflammation influence each other. Objective: We explored...